{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:23:25Z","timestamp":1774049005545,"version":"3.50.1"},"reference-count":85,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T00:00:00Z","timestamp":1396483200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1003559","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T20:29:23Z","timestamp":1396556963000},"page":"e1003559","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":80,"title":["Chemical, Target, and Bioactive Properties of Allosteric Modulation"],"prefix":"10.1371","volume":"10","author":[{"given":"Gerard J. P.","family":"van Westen","sequence":"first","affiliation":[]},{"given":"Anna","family":"Gaulton","sequence":"additional","affiliation":[]},{"given":"John P.","family":"Overington","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2014,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"Opinion: The druggable genome","volume":"1","author":"AL Hopkins","year":"2002","journal-title":"Nat Rev Drug Discovery"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd1086","article-title":"Hit and lead generation: beyond high-throughput screening","volume":"2","author":"KH Bleicher","year":"2003","journal-title":"Nat Rev Drug Discovery"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1359-6446(03)02902-7","article-title":"Rediscovering the sweet spot in drug discovery","volume":"8","author":"D Brown","year":"2003","journal-title":"Drug Discov Today"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"JP Overington","year":"2006","journal-title":"Nat Rev Drug Discovery"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2132","article-title":"Drugs, their targets and the nature and number of drug targets","volume":"5","author":"P Imming","year":"2006","journal-title":"Nat Rev Drug Discovery"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt1273","article-title":"Structure-based maximal affinity model predicts small-molecule druggability","volume":"25","author":"AC Cheng","year":"2007","journal-title":"Nat Biotech"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","article-title":"The influence of lead discovery strategies on the properties of drug candidates","volume":"8","author":"GM Keseru","year":"2009","journal-title":"Nat Rev Drug Discovery"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"10533","DOI":"10.1073\/pnas.0604452103","article-title":"Whence cometh the allosterome?","volume":"103","author":"JE Lindsley","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cbpa.2008.02.014","article-title":"Allosteric modulation of kinases and GPCRs: design principles and structural diversity","volume":"12","author":"JA Lewis","year":"2008","journal-title":"Curr Opin Chem Biol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nchembio.98","article-title":"Allosteric regulation and catalysis emerge via a common route","volume":"4","author":"NM Goodey","year":"2008","journal-title":"Nat Chem Biol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jmgm.2012.07.006","article-title":"Toward understanding the molecular basis for chemical allosteric modulator design","volume":"38","author":"Q Wang","year":"2012","journal-title":"J Mol Graphics Modell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-2836(65)80285-6","article-title":"On the nature of allosteric transitions: a plausible model","volume":"12","author":"F Bacon","year":"1965","journal-title":"J Mol Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0022-2836(66)90097-0","article-title":"On the nature of allosteric transitions: Implications of non-exclusive ligand binding","volume":"21","author":"MM Rubin","year":"1966","journal-title":"J Mol Biol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nrd746","article-title":"Allosteric binding sites on cell-surface receptors: novel targets for drug discovery","volume":"1","author":"A Christopoulos","year":"2002","journal-title":"Nat Rev Drug Discovery"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1359-6446(04)03220-9","article-title":"Allosteric modulation of G protein-coupled receptors: perspectives and recent developments","volume":"9","author":"W Soudijn","year":"2004","journal-title":"Drug Discov Today"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.tips.2007.06.009","article-title":"Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors","volume":"28","author":"T Kenakin","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"P Jeffrey Conn","year":"2009","journal-title":"Nat Rev Drug Discovery"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"D663","DOI":"10.1093\/nar\/gkq1022","article-title":"ASD: a comprehensive database of allosteric proteins and modulators","volume":"39","author":"Z Huang","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/cb300663j","article-title":"Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features","volume":"8","author":"Z Fang","year":"2012","journal-title":"ACS Chem Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/382325a0","article-title":"Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A-Cdk2 complex","volume":"382","author":"AA Russo","year":"1996","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/cb100410m","article-title":"Discovery of a Potential Allosteric Ligand Binding Site in CDK2","volume":"6","author":"S Betzi","year":"2011","journal-title":"ACS Chem Biol"},{"key":"ref22","unstructured":"Pines J. (1994) The cell cycle kinases; Semin Cancer Biol. pp. 305\u2013313."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/376313a0","article-title":"Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex","volume":"376","author":"PD Jeffrey","year":"1995","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing towards the dream","volume":"3","author":"MR Arkin","year":"2004","journal-title":"Nat Rev Drug Discovery"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1359-6446(05)03370-2","article-title":"Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors","volume":"10","author":"SRJ Hoare","year":"2005","journal-title":"Drug Discov Today"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pharmthera.2011.01.006","article-title":"Dimers and beyond: The functional puzzles of class C GPCRs","volume":"130","author":"J Kniazeff","year":"2011","journal-title":"Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.ddtec.2012.08.004","article-title":"Allosteric modulation and functional selectivity of G protein-coupled receptors","volume":"10","author":"Z-G Gao","year":"2013","journal-title":"Drug Discov Today: Technologies"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e1002333","DOI":"10.1371\/journal.pcbi.1002333","article-title":"Global Analysis of Small Molecule Binding to Related Protein Targets","volume":"8","author":"FA Kruger","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"ref29","first-page":"153","article-title":"The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection","volume":"38","author":"E De Clercq","year":"1998","journal-title":"Antiviral Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/343470a0","article-title":"Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives","volume":"343","author":"R Pauwels","year":"1990","journal-title":"Nature"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: a large-scale bioactivity database for drug discovery","volume":"40","author":"A Gaulton","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1574-1400(08)00012-1","article-title":"PubChem: integrated platform of small molecules and biological activities","volume":"4","author":"EE Bolton","year":"2008","journal-title":"Annu Rep Comput Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"D198","DOI":"10.1093\/nar\/gkl999","article-title":"BindingDB: a web-accessible database of experimentally determined protein\u2013ligand binding affinities","volume":"35","author":"T Liu","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"D1035","DOI":"10.1093\/nar\/gkq1126","article-title":"DrugBank 3.0: a comprehensive resource for \u2018Omics\u2019 research on drugs","volume":"39","author":"C Knox","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nchembio.354","article-title":"Databases: Compound bioactivities go public","volume":"6","author":"A Bender","year":"2010","journal-title":"Nat Chem Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1039\/C0MD00165A","article-title":"Proteochemometric Modeling as a Tool for Designing Selective Compounds and Extrapolating to Novel Targets","volume":"2","author":"GJP Van Westen","year":"2011","journal-title":"Med Chem Commun"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nmeth.2339","article-title":"A ligand's-eye view of protein similarity","volume":"10","author":"GJP Van Westen","year":"2013","journal-title":"Nat Methods"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/ci600197y","article-title":"\u201cBayes affinity fingerprints\u201d improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?","volume":"46","author":"A Bender","year":"2006","journal-title":"J Chem Inf Model"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nbt1284","article-title":"Relating protein pharmacology by ligand chemistry","volume":"25","author":"MJ Keiser","year":"2007","journal-title":"Nat Biotech"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"J Besnard","year":"2012","journal-title":"Nature"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pharmthera.2004.08.010","article-title":"Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential","volume":"104","author":"JNC Kew","year":"2004","journal-title":"Pharmacol Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.ddtec.2013.01.006","article-title":"Allosteric approaches to GPCR drug discovery","volume":"10","author":"JR Lane","year":"2013","journal-title":"Drug Discov Today: Technologies"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jmgm.2012.12.011","article-title":"Towards an understanding of the sequence and structural basis of allosteric proteins","volume":"40","author":"X Li","year":"2013","journal-title":"J Mol Graphics Modell"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1111\/j.1742-4658.2005.04728.x","article-title":"Allosteric functioning of dimeric class C G-protein-coupled receptors","volume":"272","author":"JP Pin","year":"2005","journal-title":"FEBS J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nature12595","article-title":"Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs","volume":"503","author":"RO Dror","year":"2013","journal-title":"Nature"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2001-2-12-reviews3013","article-title":"Family-B G-protein-coupled receptors","volume":"2","author":"A Harmar","year":"2001","journal-title":"Genome Biol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/edrv-8-4-377","article-title":"The role of calcitonin in the development and treatment of osteoporosis","volume":"8","author":"MT McDermot","year":"1987","journal-title":"Endocr Rev"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0889-8529(02)00056-7","article-title":"New anabolic therapies in osteoporosis","volume":"32","author":"MR Rubin","year":"2003","journal-title":"Endocrin Metab Clin"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2174\/0929867033456648","article-title":"Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus","volume":"10","author":"GG Holz","year":"2003","journal-title":"Curr Med Chem"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"AL Hopkins","year":"2004","journal-title":"Drug Discov Today"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/17460441.2.4.469","article-title":"Ligand efficiency indices for effective drug discovery","volume":"2","author":"C Abad-Zapatero","year":"2007","journal-title":"Expert Opin Drug Discov"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.drudis.2010.08.004","article-title":"Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation","volume":"15","author":"C Abad-Zapatero","year":"2010","journal-title":"Drug Discov Today"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejps.2003.11.007","article-title":"Allosteric modulation of G-protein coupled receptors","volume":"21","author":"AA Jensen","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric Modulation of G Protein\u2013Coupled Receptors","volume":"47","author":"LT May","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mib.2010.02.005","article-title":"Systems biology of microbial metabolism","volume":"13","author":"M Heinemann","year":"2010","journal-title":"Curr Opin Microbiol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nbt.2489","article-title":"Systematic identification of allosteric protein-metabolite interactions that control enzyme activity in vivo","volume":"31","author":"H Link","year":"2013","journal-title":"Nat Biotech"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/mol.108.054452","article-title":"Exploring the Mechanism of Agonist Efficacy: A Relationship between Efficacy and Agonist Dissociation Rate at the Muscarinic M3 Receptor","volume":"76","author":"DA Sykes","year":"2009","journal-title":"Mol Pharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1111\/j.1476-5381.2012.01897.x","article-title":"Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time","volume":"166","author":"D Guo","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.1021\/jm4011737","article-title":"Structure\u2013Kinetic Relationships\u2014An Overlooked Parameter in Hit-to-Lead Optimization: A Case of Cyclopentylamines as Chemokine Receptor 2 Antagonists","volume":"56","author":"M Vilums","year":"2013","journal-title":"J Med Chem"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0165-6147(00)89023-9","article-title":"Allosteric modulation of muscarinic acetylcholine receptors","volume":"16","author":"S Tu\u00e8ek","year":"1995","journal-title":"Trends Pharmacol Sci"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0026-895X(25)14327-7","article-title":"Modification of the binding properties of muscarinic receptors by gallamine","volume":"23","author":"JM Stockton","year":"1983","journal-title":"Mol Pharmacol"},{"key":"ref62","first-page":"1","article-title":"What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data","author":"Y Hu","year":"2013","journal-title":"AAPS J"},{"key":"ref63","first-page":"199","article-title":"Circular fingerprints: Flexible molecular descriptors with applications from physical chemistry to ADME","volume":"9","author":"RC Glen","year":"2006","journal-title":"IDrugs"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jm900492g","article-title":"Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?","volume":"53","author":"Y Mehellou","year":"2010","journal-title":"J Med Chem"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"e1002899","DOI":"10.1371\/journal.pcbi.1002899","article-title":"Significantly Improved HIV Inhibitor Efficacy Prediction Employing Proteochemometric Models Generated From Antivirogram Data","volume":"9","author":"GJP Van Westen","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.110.003285","article-title":"International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors\u2014An Update","volume":"63","author":"BB Fredholm","year":"2011","journal-title":"Pharmacol Rev"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0960-894X(00)00379-6","article-title":"Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor","volume":"10","author":"PG Baraldi","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm901252a","article-title":"Hybrid Ortho\/Allosteric Ligands for the Adenosine A1 Receptor","volume":"53","author":"R Narlawar","year":"2010","journal-title":"J Med Chem"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1021\/jm00010a017","article-title":"Structure-Activity Relationships of 9-Alkyladenine and Ribose-Modified Adenosine Derivatives at Rat A3 Adenosine Receptors","volume":"38","author":"KA Jacobson","year":"1995","journal-title":"J Med Chem"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0968-0004(01)01958-2","article-title":"Ten years of protein kinase B signalling: a hard Akt to follow","volume":"26","author":"DP Brazil","year":"2001","journal-title":"Trends Biochem Sci"},{"key":"ref71","first-page":"3986","article-title":"Akt\/Protein Kinase B Is Constitutively Active in Non-Small Cell Lung Cancer Cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation","volume":"61","author":"J Brognard","year":"2001","journal-title":"Cancer Res"},{"key":"ref72","first-page":"1367","article-title":"Design and synthesis of novel EG5 inhibitors","volume":"62","author":"M Abualhasan","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/jm201195m","article-title":"Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity","volume":"55","author":"F Wang","year":"2012","journal-title":"J Med Chem"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ejmech.2013.01.031","article-title":"Advances in the Discovery of Kinesin Spindle Protein (Eg5) Inhibitors as Antitumor Agents","volume":"62","author":"HB El-Nassan","year":"2013","journal-title":"Eur J Med Chem"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism","volume":"102","author":"ZJ Reitman","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"ref76","unstructured":"ICM (2009) Version 3.7-2d. Molsoft L.L.C., La Jolla."},{"key":"ref77","unstructured":"Pipeline Pilot. (2011) Version 8.5. Accelrys Software Inc., San Diego"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/jps.21494","article-title":"Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds","volume":"98","author":"R Mannhold","year":"2009","journal-title":"J Pharm Sci"},{"key":"ref79","unstructured":"Advanced Chemistry Development Inc (2012) PhysChem Modules. 12.01, Canada."},{"key":"ref80","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-Connectivity Fingerprints","volume":"50","author":"D Rogers","year":"2010","journal-title":"J Chem Inf Model"},{"key":"ref81","unstructured":"R Development Core Team (2006) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing."},{"key":"ref82","first-page":"18","article-title":"Classification and Regression by randomForest","volume":"2","author":"A Liaw","year":"2002","journal-title":"R News"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2105-8-25","article-title":"Bias in random forest variable importance measures: Illustrations, sources and a solution","volume":"8","author":"C Strobl","year":"2007","journal-title":"BMC Bioinformatics"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1471-2105-9-307","article-title":"Conditional variable importance for random forests","volume":"9","author":"C Strobl","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0005-2795(75)90109-9","article-title":"Comparison of the Predicted and Observed Secondary Structure of t4 Phage Lysozyme","volume":"405","author":"BW Matthews","year":"1975","journal-title":"Biochim Biophys Acta"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:31:49Z","timestamp":1746171109000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003559"}},"subtitle":[],"editor":[{"given":"Dennis R.","family":"Livesay","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2014,4,3]]},"references-count":85,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1003559","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,3]]}}}